Seagen Inc. (formerly Seattle Genetics, Inc.) is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. The company, headquartered in Bothell, Washington (a suburb of Seattle), is the industry leader in antibody-drug conjugates or ADCs, a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Antibody-drug conjugates are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity. - Source: Wikipedia
- News
- Policy
-
Commentary
- Commentary Main
- Corrections
- Editorials
- Letters
- Cheryl K. Chumley
- Kelly Sadler
- Jed Babbin
- Tom Basile
- Tim Constantine
- Joseph Curl
- Joseph R. DeTrani
- Don Feder
- Billy Hallowell
- Daniel N. Hoffman
- David Keene
- Robert Knight
- Gene Marks
- Clifford D. May
- Michael McKenna
- Stephen Moore
- Tim Murtaugh
- Peter Navarro
- Everett Piper
- Cal Thomas
- Scott Walker
- Miles Yu
- Black Voices
- Books
- Cartoons
- To the Republic
- Sports
-
Sponsored
- Corrections
- D.C. Board of Elections
- Transportation 2026
- American energy unleashed
- Infrastructure 2026
- Building the health care Americans deserve
- Revitalizing Rural America
- Unbridled Clean Energy
- Faith at Work
- Building a healthier America
- Investing in American Health
- Free Iran 2025
- Invest in Greece 2025
- Events
- Video/Podcasts
- Games
-
- Subscribe
- Sign In